Altrafin AG’s Invitae Corporation NVTA Stock Holding History

Altrafin AG’s Portfolio NVTA Stock Details NVTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,407	Closed	-$226K	–	88
2022 Q1	$226K	Buy	28,407 +576	+2%	+$5.79K	0.09%	81
2021 Q4	$425K	Buy	+27,831	New	+$602K	0.15%	79

Other funds holding NVTA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Altrafin AG's NVTA Position: Q2 2022 in Review

Altrafin AG sold out of Invitae Corporation (NVTA) in Q2 2022, closing a stake of 28,407 shares — an estimated $226K sold.

Altrafin AG first reported a position in NVTA in Q4 2021 and held it in 2 quarters. The position peaked at $425K in Q4 2021. 286 funds tracked by Wall St. Rank hold NVTA as of Q2 2022.

Altrafin AG reported no remaining Invitae Corporation position as of Q2 2022 after selling out during the quarter.
Altrafin AG sold 28,407 Invitae Corporation shares in Q2 2022, an estimated $226K.
Altrafin AG first reported a position in Invitae Corporation in Q4 2021 and held it in 2 quarters.
Altrafin AG's Invitae Corporation position peaked at $425K in Q4 2021.
286 funds tracked by Wall St. Rank held Invitae Corporation as of Q2 2022.

Based on Altrafin AG's 13F filing for Q2 2022, filed 17 Feb 2026.